Ma et al. in 2009 reported that EGFR variation in rs2293347 (D994D) was related to the clinical outcome of Gefitinib treatment in advanced non-small-cell lung cancer (NSCLC) patients, the response rate of GG genotype patients was almost double with that of other genotypes (71.2% versus 37.5%,). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.